Market Research Logo

The US Onychomycosis Market: Size, Trends and Forecasts (2018 Edition)

The US Onychomycosis Market: Size, Trends and Forecasts (2018 Edition)
Scope of the Report

The report entitled “The US Onychomycosis Market (2018 Edition)”, provides analysis of the US onychomycosis market, with detailed analysis of market size and growth, market share and economic impact of the industry. The analysis includes the market by value, by volume and by segments. The report also includes the detailed analysis of the segments of the onychomycosis market, comprising of market by value, by volume and by average prices.

In addition to this, a global analysis of the overall skin infections drugs market in terms of value followed by analysis of drugs used for the treatment of onychomycosis type of skin infection such as Kerydin and Jublia in terms of value has been done in this report.

Valeant Pharmaceuticals, Pfizer, Inc., Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Company Coverage

Valeant Pharmaceuticals
Pfizer Inc.
Novartis AG
Johnson & Johnson

Executive Summary

Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated.

Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.

There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.

The US onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period. The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.


1. Executive Summary
2. Introduction
2.1 Onychomycosis: An Overview
2.1.1 Signs and Symptoms
2.1.2 Causes of Onychomycosis
2.2 Types of Onychomycosis
Table 1: Types of Onychomycosis
2.3 Treatment For Onychomycosis
Table 2: Treatment for Onychomycosis
Table 3: Treatments Available for Onychomycosis
3. Global Market Analysis
3.1 Global Skin Infections Drugs Market: An Analysis
3.1.1 Global Skin Infections Drugs Market by Value
Table 4: Global Skin Infection Drugs Market; 2017-2026 (US$ Billion)
3.1.2 Global Skin Infections Drugs Market by Products (Drugs for Onychomycosis and Other Skin Infection Drugs)
Table 5: Global Skin Infections Drugs Market by Products; 2017 (Percentage,%)
3.2 Global Onychomycosis Market: Product Analysis
3.2.1 Global Kerydin Drugs Market by Value
Table 6: Global Kerydin Drugs Market by Value; 2017-2026 (US$ Million)
3.2.2 Global Jublia Drugs Market by Value
Table 7: Global Jublia Drugs Market by Value; 2017-2026 (US$ Million)
3.3 Global Onychomycosis Market: Pipeline Drugs Analysis
3.3.1 Global Skin Infection Market- Phase II Drugs (Onychomycosis) Pipeline Forecast
Table 8: Phase II Drugs (Onychomycosis) Pipeline Forecast; 2021-2026 (US$ Million)
3.3.2 Global Skin Infection Market- Phase III Drugs (Onychomycosis) Pipeline Forecast
Table 9: Phase III Drugs (Onychomycosis) Pipeline Forecast; 2018-2026 (US$ Million)
3.4 Onychomycosis Market: New Drugs Overview
4. US Market Analysis
4.1 The US Nail Care Market: An Analysis
4.1.1 The US Nail Care Market by Value
Table 10: The US Nail Care Market by Value; Jun16–Apr17 (US$ Million)
4.1.2 The US Nail Care Market by Segments (Jublia and Other Generic Drugs Including Kerydin)
Table 11: The US Nail Care Market by Segments; 1Q2017
4.2 The US Nail Care Market: Segment Analysis
4.2.1 The US Jublia Drug Market by Value
Table 12: The US Jublia Drug Market by Value; 3Q2016-3Q2017 (US$ Million)
4.2.2 The US Jublia Drug Market by Volume
Table 13: The US Jublia Drug Market by Volume; 4Q2014-1Q2016 (Count)
4.2.3 The US Kerydin Drug Market by Value
Table 14: The US Kerydin Drug Market by Value; 2Q2015-1Q2016 (US$ Million)
4.2.4 The US Kerydin Drug Market by Volume
Table 15: The US Kerydin Drug Market by Volume; 4Q2014-1Q2016 (Count)
4.2.5 The US Generic Drugs Market by Value
Table 16: The US Generic Drugs Market by Value; 2012-2017 (US$ Million)
4.3 The US Onychomycosis Market: An Analysis
4.3.1 The US Onychomycosis Market by Prevalence
Table 17: The US Onychomycosis Market by Prevalence; 2016 (Million)
4.3.2 The US Onychomycosis Market Prevalence by Segments
Table 18: The US Onychomycosis Market Prevalence by Segments; 2015
5. Competitive Landscape
5.1 Competition in Onychomycosis Prescription Market: An Overview
5.2 Financial Comparison of Major Players of the US Onychomycosis Market
Table 19: Financial Comparison of Major Players of the US Onychomycosis Market
6. Company Profiles
6.1 Valeant Pharmaceuticals
6.1.1 Business Overview
6.1.2 Financial Overview
Table 20: Valeant Revenue; 2013-2017 (US$ Billion)
Table 21: Valeant Revenue by Segments; 2017 (Percentage, %)
6.1.3 Business Strategy
6.2 Pfizer
6.2.1 Business Overview
6.2.2 Financial Overview
Table 22: Pfizer Revenue; 2013-2017 (US$ Billion)
Table 23: Pfizer Revenue by Segments; 2017 (Percentage, %)
6.2.3 Business Strategy
6.3 Johnson & Johnson
6.3.1 Business Overview
6.3.2 Financial Overview
Table 24: Johnson Sales; 2013-2017 (US$ Billion)
Table 25: Johnson Sales by Business Segments; 2017 (Percentage, %)
Table 26: Johnson Sales by Region; 2017 (Percentage, %)
6.3.3 Business Strategy
6.4 Novartis AG
6.4.1 Business Overview
6.4.2 Financial Overview
Table 27: Novartis Net Sales; 2013-2017 (US$ Billion)
Table 28: Novartis Sales by Segment; 2017 (Percentage, %)
Table 29 : Novartis Sales by Region; 2017 (Percentage, %)
6.4.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report